Rosnilimab for Rheumatoid Arthritis
Trial Summary
What is the purpose of this trial?
This trial is testing Rosnilimab, a new medication, to see if it can help people with moderate to severe rheumatoid arthritis by reducing joint pain and swelling. The study will check if the medication is safe and effective.
Will I have to stop taking my current medications?
No, you will not have to stop taking your current medications. Participants must continue taking at least one, but not more than two, csDMARDs (a type of medication for rheumatoid arthritis) at stable dosages throughout the trial.
Eligibility Criteria
This trial is for adults with moderate to severe Rheumatoid Arthritis who have been diagnosed at least 3 months prior and are currently on stable doses of up to two conventional synthetic DMARDs. It's not open to pregnant or breastfeeding women, those with other joint diseases, previous PD-1/PD-L1 treatment, recent cancer history, or compromised immune systems.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Rosnilimab or placebo subcutaneously for 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ANB030
Find a Clinic Near You
Who Is Running the Clinical Trial?
AnaptysBio, Inc.
Lead Sponsor